Pulmonary Hypertension Associated with Interstitial Lung Disease Market Set for Robust Growth Through 2034, Driven by Recent FDA Approvals and a Promising Clinical Pipeline Development | DelveInsight

The pulmonary hypertension associated with interstitial lung disease (PH-ILD) treatment market is experiencing significant expansion, driven by increasing disease awareness, rising prevalence, and breakthrough therapies from key PH-ILD companies, including United Therapeutics Corp., Liquidia Corporation, Insmed Incorporated, and Bellerophon Therapeutics, among others.
DelveInsight's "Pulmonary Hypertension associated with Interstitial Lung Disease Market Insight, Epidemiology And Market Forecast - 2034 [https://www.delveinsight.com/report-store/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=linkedin&utm_medium=promotion&utm_campaign=xpr]" report delivers an in-depth understanding of the PH-ILD treatment market, historical and forecasted epidemiology, as well as market trends across the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report comprehensively evaluates the current treatment landscape, emerging therapies, market share of individual treatments, and PH-ILD market forecasts through 2034, providing crucial insights for stakeholders in the PH-ILD therapeutic area.

According to DelveInsight's analysis, the PH-ILD treatment market is projected to grow substantially at a significant CAGR during the forecast period (2025-2034), driven by enhanced understanding of disease mechanisms, advancements in treatment options, and the growing elderly population. Furthermore, the US represents the largest PH-ILD treatment market share across 7MM, with USD 1.1 billion in 2023. EU4 and the UK countries captured an estimated USD 200 million.

Download the PH-ILD Market report to understand which factors are driving the PH-ILD therapeutic market @ PH-ILD Market Trends [https://www.delveinsight.com/sample-request/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=linkedin&utm_medium=promotion&utm_campaign=xpr].

According to DelveInsight's estimates, the total diagnosed PH-ILD prevalent cases were nearly 170K in 2023 across the 7MM, which are expected to rise by 2034. The United States accounted for the highest diagnosed pulmonary hypertension associated with interstitial lung disease prevalent cases, with 92K cases in 2023. The EU4 and the UK accounted for approximately 60K diagnosed prevalent cases of PH-ILD in 2023. Germany accounted for the highest number of diagnosed PH-ILD prevalent cases among the European countries, with 14K cases, followed by the UK with 13K cases, while Spain had the lowest number with approximately 9K cases in 2023.

The DelveInsight report further categorizes the PH-ILD patient population into several groups for analysis. Based on types, the total diagnosed prevalent cases of PH-ILD are divided into Idiopathic Interstitial Pneumonias (IIP), autoimmune ILD, hypersensitivity pneumonitis, and other ILDs. Among these type-specific diagnosed PH-ILD prevalent cases, IIP had the highest number of cases in 2023, with 54K cases in the US alone, followed by autoimmune ILD with 32K cases. This classification is essential for understanding the distribution, progression, and treatment responses of different PH-ILD types and is crucial for accurate epidemiological assessment.

Discover evolving trends in the PH-ILD patient pool forecasts @ PH-ILD Epidemiology Analysis [https://www.delveinsight.com/sample-request/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=linkedin&utm_medium=promotion&utm_campaign=xpr].

While there is no standard approach to assessing patients' risk of Pulmonary Hypertension, several treatment options are aimed at PH-ILD management. A milestone in pulmonary hypertension associated with interstitial lung disease treatment occurred with the FDA approval of TYVASO (treprostinil) Inhalation Solution in April 2023 and TYVASO DPI (treprostinil) Inhalation Powder in May 2024, both prostacyclin mimetics indicated for the PH-ILD treatment.

The current PH-ILD market is dominated by various treatments, including TYVASO/TYVASO DPI (treprostinil), diuretics, endothelin receptor antagonists (ERAs), phosphodiesterase type 5 inhibitors (PDE-5is), corticosteroids, and others. Among these, endothelin receptor antagonists have the highest market share, reaching nearly USD 800 million in 2023 across the 7MM.

According to the DelveInsight report, the PH-ILD therapies pipeline is robust and promising, with several novel treatments in development. The emerging drugs INOpulse from Bellerophon Therapeutics and Treprostinil Palmitil from Insmed Incorporated are expected to launch in EU4 and have the potential to create significant positive shifts in the PH-ILD treatment landscape. INOpulse is a drug-device combination therapy designed to be portable for ambulatory patients for daily use inside or outside their homes. Treprostinil Palmitil is a long-acting pulmonary vasodilator prodrug of treprostinil, offering a differentiated product profile for PH-ILD and pulmonary arterial hypertension.

Recent developments highlight the dynamic nature of the PH-ILD treatment landscape. In May 2025, Liquidia Corporation announced FDA approval of YUTREPIA (treprostinil) inhalation powder to improve exercise ability in adults with pulmonary arterial hypertension and pulmonary hypertension due to interstitial lung disease. In March 2025, Liquidia Corporation announced that the FDA has accepted its New Drug Application resubmission for YUTREPIA, intended to treat PAH and PH-ILD. Additionally, at the American Thoracic Society 2024 conference, key presentations focused on PH-ILD, highlighting the use of Pulmonary Artery Pulsatility Index to predict mortality in PH-ILD patients and the safety and efficacy of treatments like AER-901 and Liposomal Treprostinil Inhalation Suspension.

Discover recent advancements in the PH-ILD treatment landscape @ PH-ILD Recent Developments [https://www.delveinsight.com/sample-request/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=linkedin&utm_medium=promotion&utm_campaign=xpr].

Looking ahead, the PH-ILD market is expected to witness continued innovation driven by enhanced understanding of disease mechanisms and personalized medicine approaches. The expected launch of potential therapies will increase PH-ILD market size in the coming years, assisted by an increase in the diagnosed prevalent population. While significant progress has been made with current therapies, challenges remain in addressing the complex nature of this progressive disease and improving treatment accessibility across diverse patient populations. As research continues and awareness grows, the PH-ILD market is poised for remarkable expansion and therapeutic innovation through 2034.

Table of Contents

1. Key Insights

2. Executive Summary of PH-ILD

3. Competitive Intelligence Analysis for PH-ILD

4. PH-ILD Market Overview at a Glance

5. PH-ILD: Disease Background and Overview

6. PH-ILD Patient Journey

7. PH-ILD Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. PH-ILD Unmet Needs

10. Key Endpoints of PH-ILD Treatment

11. PH-ILD Emerging Therapies

12. PH-ILD: Seven Major Market Analysis

13. Attribute analysis

14. 7MM: Market Outlook

15. Access and Reimbursement Overview of PH-ILD

16. KOL Views

17. PH-ILD Market Drivers

18. PH-ILD Market Barriers

19. Appendix

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

Related Reports

Pulmonary Hypertension associated with Interstitial Lung Disease Market Pipeline Insight [https://www.delveinsight.com/sample-request/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-pipeline-insight]

PH-ILD pipeline insight provides comprehensive insights about the PH-ILD pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the PH-ILD companies, including Insmed Incorporated and Bellerophon Therapeutics, among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pulmonary-hypertension-associated-with-interstitial-lung-disease-market-set-for-robust-growth-through-2034-driven-by-recent-fda-approvals-and-a-promising-clinical-pipeline-development-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.